Researchers call for using more than surrogate outcomes to approve new antibiotics
Many recent antibiotic approvals from the FDA are based on fewer, smaller and less rigorous pivotal trials, which raises fresh questions about what new incentive …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
